From COVID to Cancer: Understanding Hypercoagulability in Modern Practice – How Coagulopathies Evolved During the Pandemic
Check back later for a possible video summary. Videos are created for most articles.Abstract
During the COVID-19 pandemic, clinicians noticed a spike in clotting disorders. This discovery prompted them to explore the causes of hypercoagulability in different diseases. This article explores how SARS-CoV-2 infection impacts blood vessels and immune function. It highlights mechanisms like inflammation in the endothelium, excess production of cytokines, activated platelets, and low tissue oxygen. It also compares these effects to those that cause blood clots in cancer patients. It highlights both shared and unique mechanisms. This shows why we need tailored anticoagulation strategies. It also suggests promising paths for future research.
Introduction
COVID-19 brought unique challenges to healthcare systems. One major issue was the high rate of thrombotic complications in hospitalized patients. These observations propelled coagulation research forward, uncovering insights beyond just viral infection. Oncologists have long fought cancer-associated thrombosis. This problem comes from tumour-related procoagulant factors, long-term inflammation, and blood flow issues.
This article discusses how the pandemic changed our view of hypercoagulability and highlights how lessons from SARS-CoV-2 coagulopathy can improve thrombosis prevention and management in cancer and other areas. We aim to foster a more nuanced, patient-centered approach to clot prevention and treatment by weaving together findings from both fields.
COVID-19 and Coagulation Disorders
Mechanisms of Hypercoagulability in COVID-19
SARS‑CoV‑2 infection triggers a cascade of events, pushing the blood toward a hypercoagulable state. The virus invades endothelial cells, causing local inflammation, which then activates the coagulation system. In severe cases, the immune response becomes excessive—a “cytokine storm” marked by surges in interleukins and tumour necrosis factor that further amplify clotting signals. Platelets, responding to both viral proteins and inflammatory mediators, become hyperactive and prone to aggregation. Concomitantly, respiratory failure drives tissue hypoxia, which itself promotes thrombus formation.
Clinical Manifestations of COVID-19-Associated Coagulopathy
Clinically, this hypercoagulability presents across a spectrum. Many patients develop deep vein thrombosis or pulmonary embolism despite lacking traditional cardiovascular risk factors. Arterial events, like stroke and heart attacks, are seen in younger people. This shows how COVID-19 can lead to clotting throughout the body.
Autopsy series and imaging studies have also revealed widespread microvascular thrombosis in the lungs and other organs, and a subset of patients progresses to a disseminated intravascular coagulation syndrome characterized by both pathological clotting and bleeding.
Cancer and Hypercoagulability
Mechanisms of Cancer-Associated Thrombosis
Long before COVID-19, cancer was known to be a major risk factor for blood clots. Tumor cells can express tissue factor and other procoagulant proteins, directly igniting clotting cascades. The chronic inflammatory milieu surrounding tumors damages the endothelium and heightens coagulation. Tumor masses may compress vessels or immobilize patients, creating areas of blood stasis that seed clots.
Clinical Manifestations of Cancer-Associated Thrombosis
Venous thromboembolism, especially deep vein thrombosis, and pulmonary embolism is a major cause of illness in cancer patients. This is especially true for those undergoing chemotherapy or those with advanced disease.
Arterial thrombosis can happen, though it’s less common. It may show up as strokes or heart attacks in cancer patients. A rare but classic paraneoplastic phenomenon—Trousseau’s syndrome—features recurrent superficial vein clots, most famously in pancreatic cancer. In blood cancers like acute promyelocytic leukemia, severe disseminated intravascular coagulation can occur. This situation is a serious clinical emergency.
Comparing COVID-19 and Cancer-Associated Hypercoagulability
While both COVID‑19 and cancer drive the blood toward thrombosis, their timelines and triggers differ. Coagulopathy in COVID‑19 emerges rapidly during acute infection, fueled by a sudden and intense cytokine release.
In contrast, cancer‑related thrombosis often builds gradually alongside tumor growth and treatment effects. Endothelial injury in viral infection is more diffuse owing to direct viral invasion and systemic inflammation. In contrast, it tends to follow localized tissue factor expression and chronic mediator release in cancer.
Platelet activation underlies both conditions but may proceed via distinct molecular pathways. Common risk factors, like older age and obesity, affect clotting in both cases. However, their impact can change based on the disease involved.
Implications for Clinical Practice
The pandemic experience has profoundly shaped modern thromboprophylaxis. In both COVID‑19 and cancer, early risk stratification—using markers such as elevated D‑dimer, impaired mobility, and comorbid conditions—guides the initiation and duration of anticoagulation.
Current guidelines support extended post‑discharge prophylaxis of up to 45 days with rivaroxaban at 10 mg once daily in high‑risk COVID‑19 survivors whose bleeding risk is low. Regular monitoring of coagulation parameters and vigilant clinical assessment allows clinicians to fine‑tune treatment, balancing thrombotic prevention against hemorrhagic complications.
Future Research Directions
The COVID-19 pandemic has opened up new avenues for research in coagulation disorders. Some potential areas for future investigation include:
Emerging research priorities include delineating the specific molecular pathways that overlap or diverge between viral and cancer‑associated coagulopathy. New biomarkers may improve early detection and allow for tailored prevention plans. Long-term cohort studies will help us understand if COVID-19 survivors have a higher risk of blood clots and show how this risk relates to cancer later on.
Finally, next‑generation therapeutics—targeting platelet–endothelium interactions or modulating selective cytokine pathways—offer the promise of more precise anticoagulant strategies with reduced bleeding liability.
Conclusion
By comparing coagulation disturbances in COVID‑19 and cancer, we gain a richer understanding of hypercoagulability’s multifaceted nature. Using these insights in daily practice can boost patient outcomes. This happens by improving risk assessment, personalizing prophylaxis, and ensuring timely intervention. Continued collaboration between clinicians and researchers will be key to transforming this knowledge into safer, more effective care.
Frequently Asked Questions:
Q: How common are thrombotic complications in COVID-19 patients?
A: Studies show that 20–40 percent of hospitalized patients with severe COVID‑19 develop venous thromboembolism. Rates depend on the severity of the illness and individual risk factors.
Q: Are all cancer patients at equal risk for thrombosis?
A: No. Thrombotic risk changes based on several factors. These include the type of cancer, its stage, treatment plan, and patient traits like mobility and coagulation status.
Q: How long should anticoagulation be continued in COVID-19 patients after hospital discharge?
A: Guidelines suggest up to 45 days of extended prophylaxis with rivaroxaban 10 mg daily for certain high-risk patients. This is only if their bleeding risk stays low.
Q: Can COVID-19 infection increase the risk of thrombosis in cancer patients?
A: Early data show that the blood clotting issues from COVID-19 may worsen cancer risks. This could raise the chances of thrombosis overall.
Q: Are there any specific laboratory tests to assess hypercoagulability in COVID-19 and cancer patients?
A: A panel that includes D‑dimer, fibrinogen, platelet count, and markers of endothelial injury (for example, von Willebrand factor) combined with clinical evaluation offers the best risk assessment.
References:
- Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135(23), 2033-2040. (https://ashpublications.org/blood/article/135/23/2033/454646/COVID-19-and-its-implications-for-thrombosis-and)
- Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., … & Lip, G. Y. (2020). COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American College of Cardiology, 75(23), 2950-2973. (https://www.jacc.org/doi/10.1016/j.jacc.2020.04.031)
- Ay, C., Pabinger, I., & Cohen, A. T. (2017). Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thrombosis and haemostasis, 117(02), 219-230. (https://pubmed.ncbi.nlm.nih.gov/27882374/)
- Thachil, J., & Cushman, M. (2020). Scientific and Standardization Committee communication: Clinical guidance on diagnosing, preventing, and treating venous thromboembolism in hospitalized patients with COVID‐19. Journal of Thrombosis and Haemostasis, 18(8), 1859-1865. (https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14929)
- Falanga, A., Marchetti, M., & Vignoli, A. (2013). Coagulation and cancer: biological and clinical aspects. Journal of Thrombosis and Haemostasis, 11(2), 223-233. (https://onlinelibrary.wiley.com/doi/10.1111/jth.12075)
- Levi, M., Thachil, J., Iba, T., & Levy, J. H. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology, 7(6), e438-e440. (https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2820%2930145-9/fulltext)
- Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., … & West, J. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet, 395(10241), 1907-1918. (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2820%2931187-9/fulltext)
- Iba, T., Levy, J. H., Levi, M., & Thachil, J. (2020). Coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis, 18(9), 2103-2109. (https://onlinelibrary.wiley.com/doi/10.1111/jth.14975)
- Khorana, A. A., & Francis, C. W. (2018). Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thrombosis research, 164, S70-S76. (https://www.sciencedirect.com/science/article/abs/pii/S0049384818300446)
- Spyropoulos, A. C., Levy, J. H., Ageno, W., Connors, J. M., Hunt, B. J., Iba, T., … & Douketis, J. (2020). Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. Journal of Thrombosis and Haemostasis, 18(8), 1859-1865. (https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14929)
